NeuroPace (NPCE) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1 year price targets for NeuroPace's shares. Their NPCE share price forecasts range from $6.00 to $10.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests that the stock has a possible downside of 17.8%.
View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts.

NeuroPace's stock was trading at $1.49 at the beginning of the year. Since then, NPCE shares have increased by 553.0% and is now trading at $9.73.
View the best growth stocks for 2023 here.

NeuroPace saw a drop in short interest in September. As of September 15th, there was short interest totaling 352,200 shares, a drop of 20.2% from the August 31st total of 441,100 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is currently 4.9 days. Currently, 3.3% of the company's shares are short sold.
View NeuroPace's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NPCE earnings forecast.

NeuroPace, Inc. (NASDAQ:NPCE) issued its earnings results on Tuesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.11. The firm had revenue of $16.51 million for the quarter, compared to analysts' expectations of $12.74 million. NeuroPace had a negative net margin of 77.25% and a negative trailing twelve-month return on equity of 133.74%.

NeuroPace issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $59.00 million-$61.00 million, compared to the consensus revenue estimate of $52.85 million.

(NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

NeuroPace trades on the NASDAQ under the ticker symbol "NPCE."

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NPCE stock can currently be purchased for approximately $9.73.

NeuroPace (NASDAQ:NPCE) has a market capitalization of $251.62 million and generates $54.93 million in revenue each year. The company earns $-47,080,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

The company employs 169 workers across the globe.

The official website for the company is www.neuropace.com. The company can be reached via phone at 650-237-2700 or via email at investors@neuropace.com.